Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T4030 versus Ganfort UD in ocular hypertension or glaucoma
2017-002823-46Phase 2Completed
- Sponsor
- Laboratoires Théa
- Start
- Jul 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bimatoprost, timolol and bimatoprost + timolol in Glaucoma and ocular hypertension (3 arms), sponsored by Laboratoires Théa. Primary endpoint: Change in intraocular pressure at 8:00 in the worse eye. Started Jul 2018; status: completed.
02
Drugs
bimatoprosttimololbimatoprost + timolol
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2017-002823-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002823-46.